- Início
- Publicações
- Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990?2021: a systematic analysis for the Global Burden of Disease Study 2021
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990?2021: a systematic analysis for the Global Burden of Disease Study 2021

Unidades de investigação
Abstract
Background: Detailed, comprehensive, and timely reporting on population health by underlying causes of disability and premature death is crucial to understanding and responding to complex patterns of disease and injury burden over time and across age groups, sexes, and locations. The availability of disease burden estimates can promote evidence-based interventions that enable public health researchers, policy makers, and other professionals to implement strategies that can mitigate diseases. It can also facilitate more rigorous monitoring of progress towards national and international health targets, such as the Sustainable Development Goals. For three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has filled that need. A global network of collaborators contributed to the production of GBD 2021 by providing, reviewing, and analysing all available data. GBD estimates are updated routinely with additional data and refined analytical methods. GBD 2021 presents, for the first time, estimates of health loss due to the COVID-19 pandemic. Methods: The GBD 2021 disease and injury burden analysis estimated years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries using 100 983 data sources. Data were extracted from vital registration systems, verbal autopsies, censuses, household surveys, disease-specific registries, health service contact data, and other sources. YLDs were calculated by multiplying cause-age-sex-location-year-specific prevalence of sequelae by their respective disability weights, for each disease and injury. YLLs were calculated by multiplying cause-age-sex-location-year-specific deaths by the standard life expectancy at the age that death occurred. DALYs were calculated by summing YLDs and YLLs. HALE estimates were produced using YLDs per capita and age-specific mortality rates by location, age, sex, year, and cause. 95% uncertainty intervals (UIs) were generated for all final estimates as the 2?5th and 97?5th percentiles values of 500 draws. Uncertainty was propagated at each step of the estimation process. Counts and age-standardised rates were calculated globally, for seven super-regions, 21 regions, 204 countries and territories (including 21 countries with subnational locations), and 811 subnational locations, from 1990 to 2021. Here we report data for 2010 to 2021 to highlight trends in disease burden over the past decade and through the first 2 years of the COVID-19 pandemic. Findings: Global DALYs increased from 2?63 billion (95% UI 2?44?2?85) in 2010 to 2?88 billion (2?64?3?15) in 2021 for all causes combined. Much of this increase in the number of DALYs was due to population growth and ageing, as indicated by a decrease in global age-standardised all-cause DALY rates of 14?2% (95% UI 10?7?17?3) between 2010 and 2019. Notably, however, this decrease in rates reversed during the first 2 years of the COVID-19 pandemic, with increases in global age-standardised all-cause DALY rates since 2019 of 4?1% (1?8?6?3) in 2020 and 7?2% (4?7?10?0) in 2021. In 2021, COVID-19 was the leading cause of DALYs globally (212?0 million [198?0?234?5] DALYs), followed by ischaemic heart disease (188?3 million [176?7?198?3]), neonatal disorders (186?3 million [162?3?214?9]), and stroke (160?4 million [148?0?171?7]). However, notable health gains were seen among other leading communicable, maternal, neonatal, and nutritional (CMNN) diseases. Globally between 2010 and 2021, the age-standardised DALY rates for HIV/AIDS decreased by 47?8% (43?3?51?7) and for diarrhoeal diseases decreased by 47?0% (39?9?52?9). Non-communicable diseases contributed 1?73 billion (95% UI 1?54?1?94) DALYs in 2021, with a decrease in age-standardised DALY rates since 2010 of 6?4% (95% UI 3?5?9?5). Between 2010 and 2021, among the 25 leading Level 3 causes, age-standardised DALY rates increased most substantially for anxiety disorders (16?7% [14?0?19?8]), depressive disorders (16?4% [11?9?21?3]), and diabetes (14?0% [10?0?17?4]). Age-standardised DALY rates due to injuries decreased globally by 24?0% (20?7?27?2) between 2010 and 2021, although improvements were not uniform across locations, ages, and sexes. Globally, HALE at birth improved slightly, from 61?3 years (58?6?63?6) in 2010 to 62?2 years (59?4?64?7) in 2021. However, despite this overall increase, HALE decreased by 2?2% (1?6?2?9) between 2019 and 2021. Interpretation: Putting the COVID-19 pandemic in the context of a mutually exclusive and collectively exhaustive list of causes of health loss is crucial to understanding its impact and ensuring that health funding and policy address needs at both local and global levels through cost-effective and evidence-based interventions. A global epidemiological transition remains underway. Our findings suggest that prioritising non-communicable disease prevention and treatment policies, as well as strengthening health systems, continues to be crucially important. The progress on reducing the burden of CMNN diseases must not stall; although global trends are improving, the burden of CMNN diseases remains unacceptably high. Evidence-based interventions will help save the lives of young children and mothers and improve the overall health and economic conditions of societies across the world. Governments and multilateral organisations should prioritise pandemic preparedness planning alongside efforts to reduce the burden of diseases and injuries that will strain resources in the coming decades. Funding: Bill Melinda Gates Foundation.
Dados da publicação
- ISSN/ISSNe:
- 0140-6736, 1474-547X
- Tipo:
- Article
- Páginas:
- 2133-2161
- Link para outro recurso:
- www.scopus.com
LANCET Elsevier Ltd.
Citações Recebidas na Web of Science: 341
Citações Recebidas na Scopus: 380
Documentos
- Não há documentos
Filiações
Filiações não disponíveis
Keywords
- RISK
Proyectos asociados
Stimulate continous monitoring in personal and physical health.
Investigador Principal: José Alberto da Silva Freitas
Estudo Observacional Académico (INNO4HEALTH) . FCT . 2021
Estudos de avaliação de exequibilidade, usabilidade e utilização de uma app para telemóvel para gestão da diabetes tipo 2.
Investigador Principal: José Alberto da Silva Freitas
Estudo Observacional Académico (FoodFriend) . FCT . 2022
Portuguese Public Hospitals Financial Performance between 2014-2020
Investigador Principal: José Alberto da Silva Freitas
Estudo Clínico Académico (Financial Performance) . 2023
Characteristics and patient-reported outcomes of long-term lung cancer survivors
Investigador Principal: Marta Maria de Pinho Dias Oliveira Carvalho Monteiro
Estudo Clínico Académico (Lung Cance) . 2023
Epilepsia musicogénica – epileptogénese e atualização da sua abordagem
Investigador Principal: Marta Maria de Pinho Dias Oliveira Carvalho Monteiro
Estudo Clínico Académico . 2021
Crises não epiléticas psicogénicas em doentes avaliados numa Unidade de Monitorização de Epilepsia
Investigador Principal: Marta Maria de Pinho Dias Oliveira Carvalho Monteiro
Estudo Clínico Académico . 2022
Tendências nas Hospitalizações por Insuficiência Cardíaca durante um Período de Dezasseis Anos: Dados de Abrangência Nacional para Portugal
Investigador Principal: José Alberto da Silva Freitas
Estudo Clínico Académico (Hospitalizações IC) . 2022
The use of secondary data in Mental Health research
Investigador Principal: José Alberto da Silva Freitas
Estudo Clínico Académico . 2023
Health priorities in the European Union - a novel framework
Investigador Principal: José Alberto da Silva Freitas
Estudo Clínico Académico . 2023
Healthcare Human Resources and Quality Indicators: Approaches to Strengthening Primary Care.
Investigador Principal: José Alberto da Silva Freitas
Estudo Clínico Académico . 2022
A machine learning-based approach to support the assessment of clinical coded data quality in the context of Diagnosis-Related Groups classification systems
Investigador Principal: José Alberto da Silva Freitas
Estudo Clínico Académico . 2020
Citar a publicação
Hussain J,Hussein NR,Huynh CK,Huynh H,Hwang B,Iannucci VC,Ihler AL,Ikiroma AI,Ikuta KS,Ilesanmi OS,Ilic IM,Ilic MD,Imam MT,Immurana M,Irham LM,Islam MR,Islam SMS,Islami F,Ismail F,Ismail NE,Isola G,Iwagami M,Iwu CCD,Iyer M,Jaafari J,Jacobsen KH,Jadidi F,Jafarinia M,Jaggi K,Jahankhani K,Jahanmehr N,Jahrami H,Jain A,Jain N,Jairoun AA,Jaiswal A,Jakovljevic M,Jatau AI,Javadov S,Javaheri T,Jayapal SK,Jayaram S,Jee SH,Jeganathan J,Jeyakumar A,Jha AK,Jiang H,Jin Y,Jonas JB,Joo T,Joseph A,Joseph N,Joshua CE,Jozwiak JJ,J?risson M,K V,Kaambwa B,Kabir A,Kabir Z,Kadashetti V,Kalani R,Kalankesh LR,Kaliyadan F,Kalra S,Kamenov K,Kamyari N,Kanagasabai T,Kandel H,Kanmanthareddy AR,Kanmodi KK,Kantar RS,Karaye IM,Karim A,Karimi SE,Karimi Y,Kasraei H,Kassel MB,Kauppila JH,Kawakami N,Kayode GA,Kazemi F,Kazemian S,Keikavoosi L,Keller C,Kempen JH,Kerr JA,Keshtkar K,Kesse E,Keykhaei M,Khajuria H,Khalaji A,Khalid A,Khalid N,Khalilian A,Khamesipour F,Khan A,Khan I,Khan M,Khan MA,Khanmohammadi S,Khatab K,Khatami F,Khatatbeh MM,Khater AM,Khayat HR,Khidri FF,Khodadoust E,Khormali M,Khorrami Z,Kifle ZD,Kim MS,Kimokoti RW,Kisa A,Kisa S,Knudsen A,Kocarnik JM,Kochhar S,Koh HY,Kolahi A,Kompani F,Koren G,Korzh O,Kosen S,Koulmane SL,Krishan K,Krishna V,Krishnamoorthy V,Kuate B,Kuddus MA,Kuddus M,Kuitunen I,Kulkarni V,Kumar M,Kumar N,Kumar R,Kurmi OP,Kusuma D,Kyu HH,La Vecchia C,Lacey B,Ladan MA,Laflamme L,Lafranconi A,Lahariya C,Lai DTC,Lal DK,Lalloo R,Lallukka T,L?m J,Lan Q,Lan T,Landires I,Lanfranchi F,Langguth B,Laplante A,Larijani B,Larsson AO,Lasrado S,Lauriola P,Le H,Le LKD,Le NHH,Le TDT,Leasher JL,Ledda C,Lee M,Lee PH,Lee S,Lee SW,Lee W,Lee YH,LeGrand KE,Lenzi J,Leong E,Leung J,Li M,Li W,Li X,Li Y,Lim L,Lim SS,Lindstrom M,Linn S,Liu G,Liu R,Liu S,Liu W,Liu X,Llanaj E,C,L?pez R,Loreche AM,Lorenzovici L,Lozano R,Lubinda J,Lucchetti G,Lunevicius R,Lusk JB,lv H,Ma ZF,Machairas N,Madureira ?M,Maga?a JA,Maghazachi AA,Maharjan P,Mahasha PW,Maheri M,Mahjoub S,Mahmoud MA,Mahmoudi E,Majeed A,Makris KC,Malakan E,Malhotra K,Malik AA,Malik I,Malta DC,Manla Y,Mansour A,Mansouri P,Mansournia MA,Mantilla AM,Mantovani LG,Manu E,Marateb HR,Mardi P,Martinez G,Martinez R,Martini D,Martins FR,Martorell M,Marx W,Maryam S,Marzo RR,Mathangasinghe Y,Mathieson S,Mathioudakis AG,Mattumpuram J,Maugeri A,Mayeli M,Mazidi M,Mazzotti A,McGrath JJ,McKee M,McKowen A,McPhail MA,Mehrabani K,Mehrabi E,Mekene T,Mendoza W,Menezes RG,Mensah GA,Mentis AA,Meo SA,Meresa HA,Meretoja A,Meretoja TJ,Mersha AM,Mestrovic T,Mettananda KCD,Mettananda S,Michalek IM,Miller PA,Miller TR,Mills EJ,Minh LHN,Mirijello A,Mirrakhimov EM,Mirutse MK,Mirza Aghazadeh Attari M,Mirzaei M,Mirzaei R,Misganaw A,Mishra AK,Mitchell PB,Mittal C,Moazen B,Moberg ME,Mohamed J,Mohamed MFH,Mohamed NS,Mohammadi E,Mohammadi S,Mohammed H,Mohammed S,Mohr RM,Mokdad AH,Molinaro S,Momtazmanesh S,Monasta L,Mondello S,Moodi A,Moradi M,Moradi Y,Moradi M,Moraga P,Morawska L,Moreira RS,Morovatdar N,Morrison SD,Morze J,Mosapour A,Mosser JF,Mossialos E,Motappa R,Mougin V,Mouodi S,Mrejen M,Msherghi A,Mubarik S,Mueller UO,Mulita F,Munjal K,Murillo E,Murlimanju B,Mustafa G,Muthu S,Muzaffar M,Myung W,Nagarajan AJ,Naghavi P,Naik GR,Nainu F,Nair S,Najmuldeen HHR,Nangia V,Naqvi AA,Narayana AI,Nargus S,Nascimento GG,Nashwan AJ,Nasrollahizadeh A,Natto ZS,Nayak BP,Nayak VC,Nduaguba SO,Negash H,Negoi I,Negoi RI,Nejadghaderi SA,Nesbit OD,Netsere HB,Ng M,Nguefack G,Ngunjiri JW,Nguyen DH,Nguyen HQ,Niazi RK,Nikolouzakis TK,Nikoobar A,Nikoomanesh F,Nikpoor AR,Nnaji CA,Nnyanzi LA,Noman EA,Nomura S,Norrving B,Nri CA,Ntaios G,Ntsekhe M,Nurrika D,Nzoputam CI,Nzoputam OJ,Oancea B,Odetokun IA,O'Donnell MJ,Oguntade AS,Oguta JO,Okati H,Okeke SR,Okekunle AP,Okonji OC,Olagunju AT,Olasupo OO,Olatubi MI,Oliveira GMM,Olufadewa II,Olusanya BO,Olusanya JO,Omar HA,Omer GL,Omonisi A,Onie S,Onwujekwe OE,Ordak M,Orish VN,Ortega DV,Ortiz A,Ortiz E,Osman WMS,Ostroff SM,Osuagwu UL,Otoiu A,Otstavnov N,Otstavnov SS,Ouyahia A,Ouyang G,Owolabi MO,P MP,Padron A,Padubidri JR,Palicz T,Palladino C,Pan F,Pandi SR,Pangaribuan HU,Panos GD,Panos LD,Pantea AM,Pardhan S,Parikh RR,Pashaei A,Pasovic M,Passera R,Patel J,Patel SK,Patil S,Patoulias D,Patthipati VS,Pawar S,Pazoki H,Pease SA,Peden AE,Pedersini P,Peng M,Pensato U,Pepito VCF,Peprah EK,Peprah P,Perdig?o J,Pereira MO,Perianayagam A,Perico N,Pesudovs K,Petermann FE,Petri WA,Pham HT,Philip AK,Phillips MR,Pigeolet M,Pigott DM,Pillay JD,Piracha ZZ,Pirouzpanah S,Plass D,Plotnikov E,Poddighe D,Polinder S,Postma MJ,Pourtaheri N,Prada SI,Pradhan PMS,Prakash V,Prasad M,Prates E,Priscilla T,Pritchett N,Puri P,Puvvula J,Qasim NH,Qattea I,Qazi AS,Qian G,Rabiee M,Radhakrishnan RA,Radhakrishnan V,Raeisi H,Rafferty Q,Raggi A,Raghav PR,Rahim MJ,Rahman MM,Rahman M,Rahman M,Rahman MA,Rahmani S,Rahmanian M,Rahmawaty S,Rajaa S,Ramadan MM,Ramasamy SK,Ramasubramani P,Ramazanu S,Rana K,Ranabhat CL,Rancic N,Rane A,Rao CR,Rao K,Rao M,Rao SJ,Rashidi M,Rathnaiah G,Rauniyar SK,Rawaf DL,Rawaf S,Razo C,Reddy MMRK,Redwan E,Reifels L,Reiner RC,Remuzzi G,Renzaho A,Reshmi B,Reyes LF,Rezaei N,Rezaei P,Rezaeian M,Rickard J,Rodrigues CF,Rodriguez J,Roever L,Ronfani L,Roshandel G,Rotimi K,Rout HS,Roy B,Roy N,Roy P,Rubagotti E,S C,Saad A,Saber MM,Sabour S,Sacco S,Sachdev PS,Saddik B,Saddler A,Sadee BA,Sadeghi E,Sadeghi M,Saeb MR,Saeed U,Safi SZ,Sagar R,Sagoe D,Saif Z,Sajid MR,Sakshaug JW,Salam N,Salami AA,Salaroli LB,Saleh MA,Salem MR,Salem MZY,Sallam M,Samadzadeh S,Samargandy S,Samodra YL,Samy AM,Sanabria J,Sanna F,Santos IS,Santric MM,Sarasmita MA,Sarikhani Y,Sarmiento R,Sarode GS,Sarode SC,Sarveazad A,Sathian B,Sathyanarayan A,Satpathy M,Sawhney M,Scarmeas N,Schaarschmidt BM,Schmidt MI,Schneider I,Schumacher AE,Schwebel DC,Schwendicke F,Sedighi M,Senapati S,Senthilkumaran S,Sepanlou SG,Sethi Y,Setoguchi S,Seylani A,Shadid J,Shafie M,Shah H,Shah NS,Shah PA,Shahbandi A,Shahid S,Shahid W,Shahwan MJ,Shaikh MA,Shakeri A,Shalash AS,Sham S,Shamim MA,Shamshirgaran MA,Shamsi MA,Shanawaz M,Shankar A,Shannawaz M,Sharath M,Sharifan A,Sharifi J,Sharma M,Sharma R,Sharma S,Sharma U,Sharma V,Shastry RP,Shavandi A,Shayan AM,Shayan M,Shehabeldine A,Shetty PH,Shibuya K,Shifa JE,Shiferaw D,Shiferaw WS,Shigematsu M,Shiri R,Shitaye NA,Shittu A,Shivakumar KM,Shivarov V,Shokati Z,Shool S,Shrestha S,Shuval K,Ferrari AJ,Santomauro DF,Aali A,Abate YH,Abbafati C,Abbastabar H,Abd S,Abdelmasseh M,Abd S,Abdollahi A,Abdullahi A,Abegaz KH,Abelda?o RA,Aboagye RG,Abolhassani H,Abreu LG,Abualruz H,Abu E,Abu NM,Ackerman IN,Addo IY,Addolorato G,Adebiyi AO,Adepoju AV,Adewuyi HO,Afyouni S,Afzal S,Agodi A,Ahmad A,Ahmad D,Ahmad F,Ahmad S,Ahmed A,Ahmed LA,Ahmed MB,Ajami M,Akinosoglou K,Akkaif MA,Al Hasan SM,Alalalmeh SO,Al Aly Z,Albashtawy M,Aldridge RW,Alemu MD,Alemu YM,Alene KA,Al Gheethi A,Alharrasi M,Alhassan RK,Ali MU,Ali R,Ali SSS,Alif SM,Aljunid SM,Al Marwani S,Almazan JU,Alomari MA,Al Omari B,Altaany Z,Alvis N,Alvis NJ,Alwafi H,Al Wardat MS,Al Worafi YM,Aly S,Alzoubi KH,Amare AT,Amegbor PM,Ameyaw EK,Amin TT,Amindarolzarbi A,Amiri S,Amugsi DA,Ancuceanu R,Anderlini D,Anderson DB,Andrade PP,Andrei CL,Ansari H,Antony CM,Anwar S,Anwar SL,Anwer R,Anyanwu PE,Arab JP,Arabloo J,Arafat M,Araki DT,Aravkin AY,Arkew M,Armocida B,Arndt MB,Arooj M,Artamonov AA,Aruleba RT,Arumugam A,Ashbaugh C,Ashemo MY,Ashraf M,Asika MO,Askari E,Astell T,Athari SS,Atorkey P,Atout MMW,Atreya A,Aujayeb A,Ausloos M,Avan A,Awotidebe AW,Awuviry K,Ayala BP,Ayuso JL,Azadnajafabad S,Azevedo RMS,Babu AS,Badar M,Badiye AD,Baghdadi S,Bagheri N,Bah S,Bai R,Baker JL,Bakkannavar SM,Bako AT,Balakrishnan S,Bam K,Banik PC,Barchitta M,Bardhan M,Bardideh E,Barker SL,Barqawi HJ,Barrow A,Barteit S,Barua L,Bashiri S,Basiru A,Basu S,Bathini PP,Batra K,Baune BT,Bayileyegn NS,Behnam B,Behnoush AH,Beiranvand M,Bejarano DF,Bell ML,Bello OO,Beloukas A,Bensenor IM,Berezvai Z,Bernabe E,Bernstein RS,Bettencourt PJG,Bhagavathula AS,Bhala N,Bhandari D,Bhargava A,Bhaskar S,Bhat V,Bhatti GK,Bhatti JS,Bhatti MS,Bhatti R,Bhutta ZA,Bikbov B,Bishai JD,Bisignano C,Bitra VR,Bj?rge T,Bodolica V,Bodunrin AO,Bogale EK,Bonakdar M,Bonny A,Bora B,Borhany H,Boxe C,Brady OJ,Bragazzi NL,Braithwaite D,Brant LC,Brauer M,Breitner S,Brenner H,Brown J,Brugha T,Bulamu NB,Buonsenso D,Burkart K,Burns RA,Busse R,Bustanji Y,Butt ZA,Byun J,Caetano dos Santos FL,Calina D,C?mera LA,Campos IR,Cao C,Capodici A,Carr S,Carreras G,Carugno A,Carvalho M,Castaldelli JM,Casta?eda CA,Castelpietra G,Catapano AL,Cattaruzza MS,Caye A,Cegolon L,Cembranel F,Cenderadewi M,Cerin E,Chakraborty PA,Chan JSK,Chan RNC,Chandika RM,Chandrasekar EK,Charalampous P,Chattu VK,Chatzimavridou V,Chen AW,Chen A,Chen CS,Chen H,Chen NM,Cheng E,Chimed O,Chimoriya R,Ching PR,Cho WCS,Choi S,Chong B,Chong YY,Choudhari SG,Chowdhury R,Christensen SWM,Chu D,Chukwu IS,Chung E,Chutiyami M,Claassens MM,Cogen RM,Columbus A,Conde J,Cortesi PA,Cousin E,Criqui MH,Cruz N,Dadras O,Dai S,Dai X,Dai Z,Dalaba MA,Damiani G,Das JK,Das S,Dashti M,D?vila CA,Davletov K,De Leo D,Debele AT,Debopadhaya S,DeCleene NK,Deeba F,Degenhardt L,Del Bo' C,Delgado I,Demetriades AK,Denova E,Dervenis N,Desai HD,Desai R,Deuba K,Dhama K,Dharmaratne SD,Dhingra S,Dias da Silva D,Diaz D,Diaz LA,Diaz MJ,Dima A,Ding DD,Dirac MA,Do THP,do CB,Dohare S,Dominguez RV,Dong W,Dongarwar D,D'Oria M,Dorsey ER,Doshmangir L,Dowou RK,Driscoll TR,Dsouza HL,Dsouza V,Dube J,Dumith SC,Duncan BB,Duraes AR,Duraisamy S,Durojaiye OC,Dzianach PA,Dziedzic AM,Eboreime E,Ebrahimi A,Edinur HA,Edvardsson D,Eikemo TA,Eini E,Ekholuenetale M,Ekundayo TC,El Sayed I,Sibhat MM,Siddig EE,Sigfusdottir ID,Silva D,Silva JP,Silva LMLR,Silva S,Simpson CR,Singal A,Singh A,Singh BB,Singh H,Singh JA,Singh M,Singh P,Skou ST,Sleet DA,Slepak E,Solanki R,Soliman SSM,Song S,Song Y,Sorensen RJD,Soriano JB,Soyiri IN,Spartalis M,Sreeramareddy CT,Stark BA,Starodubova AV,Stein C,Stein DJ,Steiner C,Steiner TJ,Steinmetz JD,Steiropoulos P,Stockfelt L,Stokes MA,Subedi NS,Subramaniyan V,Suemoto CK,Suleman M,Suliankatchi R,Sultana A,Sundstr?m J,Swain CK,Szarpak L,Tabaee P,Tabar?s R,Tabatabaei O,Tabatabaeizadeh S,Tabatabai S,Tabche C,Tabish M,Tadakamadla SK,Taheri Y,Taheri M,Taherkhani A,Taiba J,Talaat IM,Talukder A,Tampa M,Tamuzi JL,Tan K,Tandukar S,Tang H,Tavakoli R,Tavangar SM,Teimoori M,Temsah M,Teramoto M,Thangaraju P,Thankappan KR,Thapar R,Thayakaran R,Thirunavukkarasu S,Thomas N,Thomas NK,Thum CCC,Tichopad A,Ticoalu JHV,Tillawi T,Tiruye TY,Tobe R,Tonelli M,Topor R,Torre AE,Touvier M,Tovani MR,Tran JT,Tran MTN,Tran NM,Tran N,Trico D,Tromans SJ,Truyen TTTT,Tsatsakis A,Tsegay GM,Tsermpini EE,Tumurkhuu M,Tyrovolas S,Udoh A,Umair M,Umakanthan S,Umar TP,Undurraga EA,Unim B,Unnikrishnan B,Unsworth CA,Upadhyay E,Urso D,Usman JS,Vahabi SM,Vaithinathan AG,Van den Eynde J,Varga O,Varma RP,Vart P,Vasankari TJ,Vasic M,Vaziri S,Vellingiri B,El Tantawi M,Elbarazi I,Elemam NM,ElGohary GMT,Elhadi M,Elmeligy O,ELNahas G,Elshaer M,Elsohaby I,Engelbert L,Erkhembayar R,Eshrati B,Estep K,Fabin N,Fagbamigbe AF,Falzone L,Fareed M,Farinha C,Faris M,Faro A,Farrokhi P,Fatehizadeh A,Fauk NK,Feigin VL,Feng X,Fereshtehnejad S,Feroze AH,Ferreira N,Ferreira PH,Fischer F,Flavel J,Flood D,Flor LS,Foigt NA,Folayan MO,Force LM,Fortuna D,Foschi M,Franklin RC,Freitas A,Fukumoto T,Furtado JM,Gaal PA,Gadanya MA,Gaidhane AM,Gaihre S,Galali Y,Ganbat M,Gandhi AP,Ganesan B,Ganie MA,Ganiyani MA,Gardner WM,Gebi TG,Gebregergis MW,Gebrehiwot M,Gebremariam TBB,Gebremeskel TG,Gela YY,Georgescu SR,Getachew A,Gething PW,Getie M,Ghadiri K,Ghadirian F,Ghailan KY,Ghajar A,Ghasemi M,Ghasempour G,Ghasemzadeh A,Ghazy RM,Gholamrezanezhad A,Ghorbani M,Ghotbi E,Gibson RM,Gill TK,Ginindza TG,Girmay A,Glasbey JC,G?b?l?s L,Godinho MA,Goharinezhad S,Goldust M,Golechha M,Goleij P,Gona PN,Gorini G,Goulart AC,Grada A,Grivna M,Guan S,Guarducci G,Gubari M,Gudeta MD,Guha A,Guicciardi S,Gulati S,Gulisashvili D,Gunawardane DA,Guo C,Gupta AK,Gupta B,Gupta I,Gupta M,Gupta R,Gupta VB,Gupta VK,Guti?rrez RA,Habibzadeh F,Habibzadeh P,Haddadi R,Hadi NR,Haep N,Hafezi N,Hafiz A,Hagins H,Halboub ES,Halimi A,Haller S,Halwani R,Hamilton EB,Hankey GJ,Hannan MA,Haque MN,Harapan H,Haro JM,Hartvigsen J,Hasaballah AI,Hasan I,Hasanian M,Hasnain MS,Hassan A,Haubold J,Havmoeller RJ,Hay SI,Hayat K,Hebert JJ,Hegazi OE,Heidari G,Helfer B,Hemmati M,Hendrie D,Henson CA,Hezam K,Hiraike Y,Hoan NQ,Holla R,Hon J,Hossain MM,Hosseinzadeh H,Hosseinzadeh M,Hostiuc M,Hostiuc S,Hsu JM,Huang J,Hugo FN,Hushmandi K,Venketasubramanian N,Veroux M,Verras G,Vervoort D,Villafa?e JH,Violante FS,Vlassov V,Vollset SE,Volovat SR,Vongpradith A,Waheed Y,Wang C,Wang F,Wang N,Wang S,Wang Y,Ward P,Wassie EG,Weaver MR,Weerakoon KG,Weintraub RG,Weiss DJ,Weldemariam AH,Wells KM,Wen YF,Whisnant JL,Whiteford HA,Wiangkham T,Wickramasinghe DP,Wickramasinghe ND,Wilandika A,Wilkerson C,Willeit P,Wimo A,Woldegebreal DH,Wolf AW,Wong YJ,Woolf AD,Wu C,Wu F,Wu X,Wu Z,Wulf S,Xia Y,Xiao H,Xu X,Xu YY,Yadav L,Yadollahpour A,Yaghoubi S,Yamagishi K,Yang L,Yano Y,Yao Y,Yaribeygi H,Yazdanpanah MH,Ye P,Yehualashet SS,Yesuf SA,Yezli S,Yi?it A,Yi?it V,Yigzaw ZA,Yismaw Y,Yon DK,Yonemoto N,Younis MZ,Yu C,Yu Y,Yusuf H,Zahid MH,Zakham F,Zaki L,Zaki N,Zaman BA,Zamora N,Zand R,Zandieh GGZ,Zar HJ,Zarrintan A,Zastrozhin MS,Zhang H,Zhang N,Zhang Y,Zhao H,Zhong C,Zhong P,Zhou J,Zhu Z,Ziafati M,Zieli?ska M,Zimsen SRM,Zoladl M,Zumla A,Zyoud SH,Vos T,Murray CJL. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990?2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024. 403. (10440):p. 2133-2161. IF:168,900. (1).